跳至主要内容
临床试验/NCT04140461
NCT04140461Unknown3 期

Antifungal Treatment of Cryptococcal Meningitis

Shanghai Public Health Clinical Center1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2020年1月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
入组人数
40
试验地点
1
主要终点
Number of subjects died at weeks 48

研究概览

简要总结

Cryptococcal meningitis (CM) is one of the leading opportunistic infections and one of the most common causes of death in AIDS patients.

Amphotericin B (AmB) is the corner stone in CM treatment. The effect of AmB was dose-dependent. Recent retrospective study indicated that longer duration rather than higher dose of AmB is necessary to reduce the mortality of CM. We aimed to explore the efficacy and safety of small dose but longer duration of AmB for the treatment of HIV-associated CM.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Confirmed HIV infection
  • Naive to antiretroviral therapy
  • Cryptococcal antigen, smear or culture positive in cerebrospinal fluid
  • Agree to participate the study

排除标准

  • Having receiving antifungal treatment for ≥3 days
  • ALT or AST > 5* upper limit of detection (ULD), or neutrophil< 0.5*10E9 cells/L, or hemoglobin < 90g/L or platelet <50*10E9/L or serum creatinine > ULD
  • Pregnancy or breastfeeding
  • Concomitant medications that are contraindicated with any research drug
  • Any other contraindications for using amphotericin B or 5FC
  • Inability to follow-up as accessed by the investigator

研究组 & 干预措施

Trial

Experimental

Amphotericin B 0.5 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 4 weeks

干预措施: Amphotericin B (Drug)

Trial

Experimental

Amphotericin B 0.5 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 4 weeks

干预措施: Flucytosine (Drug)

Control

Active Comparator

Amphotericin B 0.7 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 2 weeks

干预措施: Amphotericin B (Drug)

Control

Active Comparator

Amphotericin B 0.7 mg/kg IVGTT QD + Flucytosine 100mg/kg PO QD for 2 weeks

干预措施: Flucytosine (Drug)

结局指标

主要结局

Number of subjects died at weeks 48

时间窗: 48 weeks after randomization

Mortality in intent to treat population

次要结局

  • Number of subjects with disability at weeks 48(48 weeks after randomization)
  • Number of subjects with CSF culture positive for Cryptococcus at weeks 2(2 weeks after randomization)

研究者

申办方类型
Other Gov
责任方
Principal Investigator
主要研究者

Jun Chen

Assistant of the department

Shanghai Public Health Clinical Center

研究点 (1)

Loading locations...

相似试验